Background {#Sec1}
==========

Annually, about 100 million Chinese patients will receive treatment by tissue repair and regeneration technologies because of the sharp increase in various injuries, accidents, and diseases of aging. However, the current paradigm of "healing by scar tissue replacement," regardless of superficial tissues or visceral organs, is stagnating and is far away from the ultimate goal of "regenerating the impaired organ." Regenerative medicine (RM) is gradually being used to restore the intrinsic repair ability with stem cell transplantation, tissue engineering, activating factors, cell reprogramming, and genetic treatments. RM holds sound promise of restoring organ function that is impaired because of congenital disorders, acquired disease, trauma, and aging by replacing or regenerating cells, tissues, and even organs. RM is expected to transcend traditional organ transplantation and replacement. Stem cell technology and tissue engineering have an outstanding role in RM. RM will become one of the most promising areas of life science in the twenty-first century \[[@CR1], [@CR2]\].

In the past 20 years, the RM market has continued to grow in China and other countries such as the USA, Europe, Japan, and Singapore. As the largest developing country, China has impressed the world with its findings in stem cells, tissue engineering, active molecules, and gene therapy as well as its national strategies and regulation of RM. These achievements may benefit China in both disease treatment and society development \[[@CR3]\].

Review {#Sec2}
======

Strategies, guidance, funding, and industrialization of RM in china {#Sec3}
-------------------------------------------------------------------

### National strategies {#Sec4}

The central government of China supports the development of RM. In the *2006 National Plan for Long- and Medium-Term Scientific and Technological Development (2006--2020)*, stem cells and RM technologies were the important fields among the five biotechnologies (<http://www.gov.cn/gzdt/2009-08/21/content_1398305.htm>). Also, local governments have adopted stem cell research as one of the priorities of technological development and provided active support. Relevant government departments and academia have paid close attention to and encouraged the development of RM. In the *Science & Technology on Public Health in China: A Roadmap to 2050*, issued by the Chinese Academy of Sciences (CAS) \[[@CR4]\], and the *Study on the Long- and Medium-Term Development Strategy for China Engineering Science and Technology*, issued by the Chinese Academy of Engineering (CAE) (<http://news.sciencenet.cn/htmlnews/2012/12/273300-3.shtm>), RM was considered a major research field. In the *Roadmap of Translational Medicine in China* issued by CAE, RM and biotherapy are main fields. Industrialization of RM is a part of the "12th Five-Year Planning" and will be nurtured as a source of economic growth.

The strategic science and technology projects from CAS can be divided into "Forward-Looking Strategic Priority Research Program of Science and Technology" and "Construction of Research Centers for Basic and Forefront Scientific Research." Academia held three Xiangshan Science Conferences on RM, in 2005, 2010, and 2015, to discuss the philosophy, scope, and major breakthroughs needed for the development of RM in China and the key scientific issues to be addressed. In addition, the Xiangshan Science Conference organized seminars on stem cell biology and cloning, strategies for research and development of gene therapy and biomaterials, and tissue engineering.

### Regulatory and scientific guidance {#Sec5}

Policies and regulations reflect that China is gradually strengthening the management of RM research and clinical application. Since 1999, when the Ministry of Health (MH) promulgated the first *Umbilical cord blood stem cell bank management approach (Trial),* about 30 rules and regulations have been issued by the Ministry of Science and Technology (MST), the MH, and the State Food and Drug Agency (SFDA) (Table [1](#Tab1){ref-type="table"}).Table 1Management specification of stem cell transplantation techniquesTimeManagement specification of stem cell transplantation techniques2006Unrelated Hematopoietic Stem Cell Transplantation TechniqueUnrelated Hematopoietic Stem Cell Transplantation Collection Technique2009Cord Blood Stem Cell Therapy Technology (Trial)Tissue-engineering Tissue Transplantation Therapy Technique (Trial)

In 2011, the First National Stem Cell Research Guidance and Coordination Committee was established for the overall design and scientific planning of stem cell research in China. In December 2011, the *Notice on Carrying out Self-inspection and Self-rectification Campaign Regarding Stem Cell Clinical Research and Application* was issued. In 2013, the stem cell clinical research and application rectification lead group of the MH and SFDA formulated the regulations *Management Specification of Stem Cell Clinical Trials (Trial)*, *Management Specification of Stem Cell Clinical Trial Research Base (Trial)*, and *Stem Cell Preparation Quality Control and Pre-clinical Research Guidelines (Trial)*. These regulations will be implemented soon and help in the development of RM in China. In 2015, China MH opens the window to allow the stem cell clinic trial and stem cell research bases which will promote the development of stem cell research and translational application in China.

### Funding support and resources {#Sec6}

Multiple sources are funding RM studies and translational application. After 1999, the MST approved the National Program on Key Basic Research Project (973 Program) related to tissue engineering, and the stem cell field had the largest number of "973 Program" projects. Research into the clinical transformation and application of stem cell therapy was established in the biotechnology and medical technology field of the "863 Program." The National Natural Science Foundation (NNSF) funded about 200 million RMB for this study, including 5627 items (Fig. [1a](#Fig1){ref-type="fig"}, [b](#Fig1){ref-type="fig"}). Up to now, about 3 billion RMB from the MST, CAS, and NNSF has been invested in this field. Both the amount of funding and number of projects are increasing annually. Other funding for RM from companies is about 500 million RMB. In 2015, NNSF plans to invest RM research as its "Great Research Plan," and MST has issued its new scientific research grand with about 21 billion RMB in RM field.Fig. 1National Natural Science Foundation of China investment in regenerative medicine from 2000 to 2014. **a** Amount of funding. **b** Number of funds

### Translating outcomes into industrialization {#Sec7}

The establishment of centers and technological translational application are important for RM development. Since 1999, China has established about 30 RM centers. These centers are involved in stem cell research and its translational application (e.g., national stem cell east center and national stem cell centers in Tianjin, Qingdao, Wuxi, Taizhou, etc.) (<http://www.bioon.com/biology/cell/28500.shtml>); national stem cell and RM technology innovation strategic alliance (sponsors and governing members include 27 first-class research institutes, well-known three-A hospitals, several "211 Project" key universities and industry leaders); and a tissue engineering innovation center in Shanghai. In 2011, the first academic workstation for the industrialization of stem cell technology was launched in the Inner Mongolia Autonomous Region. Companies such as Cyagen Biosciences (Guangzhou) and Hangzhou Biowish Technology (Biowish) are specialized in the development and sales of stem cell products. In 2009, NeoStem announced that it had reached an exclusive agreement for strengthening biomedical cooperation with Shanghai enterprises. This agreement aims to establish a network of stem cell collection and treatment centers in Shanghai, Jiangsu, Zhejiang, Fujian, Anhui, and Jiangxi provinces. In 2010, the Beike Stem Cell Bank and Stem Cell Preparation Laboratory successfully passed the ISO 9001 quality management system certification and obtained the qualification certification issued by China Quality Certification Center, becoming the first comprehensive stem cell bank to pass ISO 9001 quality management system certification in China (<http://www.bioon.com/industry/enterprisenews/432100.shtml>).

Production in academic fields {#Sec8}
-----------------------------

Publication of valued scientific papers is one of the very important indicators to evaluate investment and production in academic fields. The total number of scientific papers dealing with RM has increased quickly in China, as has the number published in leading scientific journals in China and internationally (Fig. [2](#Fig2){ref-type="fig"}). Since the 1960s, the USA has published 599 articles about stem cells in *Cell* and its subjournals (36), Germany published 45, Japan 36, and China only 17. Since 2000, the number of annual patent applications for stem cells has increased quickly and amounted to 1333 in 2009. In 2011, the Chinese literature related to stem cells outnumbered that of published by German, Japanese, and UK researchers and ranked second. In 2012, it had increased. In terms of citations, the USA ranked the first, with a mean of 32.2 citations per item. However, citations for Chinese publications are increasing annually, and the mean number is currently 10.19. For patent applications, as of March 2010, the number of China stem cell-related patent applications and patent applications as a patent priority country was ranked the sixth and third in the world, respectively. The USA, Japan, and China have applied for more patents as patent priority countries (<http://www.chinainfo.gov.cn/Report/ArticlesView.aspx?aid=7924>).Fig. 2Outputs of regenerative medicine research papers compared with major countries (ISI Web of Knowledge). **a** Stem cells. **b** Tissue engineering

Also, many monographs on stem cells or tissue engineering and RM have been published which play some role in pushing the research of RM in China (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}).Table 2Main monographs on regenerative medicine published in ChinaTimeNameAuthorPublishing company2008.03Regenerative Medicine: From Basic to Clinic ResearchFu Xiaobing, Wang Zhengguo, Wu Zuze \[[@CR5]\]Shanghai Scientific and Technical Publishers2010.05Regenerative Medicine: Theory and TechnologyPei Xuetao \[[@CR6]\]Science Press2012.03Regenerative MedicineDing Fei, Liu Wei, Gu Xiaosong \[[@CR7]\]People's Medical Publishing House2013.08Regenerative Medicine: Basic and Clinical ResearchFu Xiaobing, Wang Zhengguo, Wu Zuze \[[@CR8]\]People's Medical Publishing House2014.10Tissue Engineering and Regenerative MedicineJin yan \[[@CR9]\]People's Medical Publishing House2015.03Chinese Discipline Development Strategy Regenerative MedicineChinese Academy of Sciences \[[@CR10]\]Science PressTable 3Main monographs on stem cells published in ChinaTimeNameAuthorPublishing company1988.01Basic Hematopoietic Stem Cell TransplantWu Zuze \[[@CR11]\]People's Medical Publishing House2000.04Stem Cells and Developmental BiologyYe Xinsheng, Xu Tian, Tang Xifang, Pei Xuetao \[[@CR12]\]Military Medical Science Press2000.09Peripheral Blood Stem Cell TransplantationDa Wanming, Pei Xuetao \[[@CR13]\]People's Medical Publishing House2000.11Hematopoietic Stem Cells Theory and Transplant TechniqueHan Zhongchao \[[@CR14]\]Henan Science and Technology Press2003.07Stem Cell BiologyPei Xuetao \[[@CR15]\]Science Press2005.03Stem Cells Theory and TechniqueWang Tinghua, Li Liyan \[[@CR16]\]Science Press2005.05Stem Cells BiologyHu Huozhen \[[@CR17]\]Sichuan University Press2006.05Principles, Technology and Clinic of Stem CellZhao Chunhua \[[@CR18]\]Chemical Industry Press2006.07Neural Stem Cell Foundation and ApplicationZhu Xiaofeng \[[@CR19]\]Science Press2006.12Neural Stem CellXu Ruxiang \[[@CR20]\]Military Medical Science Press2007.03Hematopoietic Stem Cell Biology and Research MethodsWang Yaping \[[@CR21]\]Science Press2007.07Stem Cell Aging and DiseaseWang Yaping \[[@CR22]\]Science Press2008.02Fundamental and Clinic Research of Stem CellsYu Yue \[[@CR23]\]Press of University of Science and Technology of China2010.07New Technologies of Stem cell ApplicationYang Xiaofeng, Zhang Sufen, Guo Zikuan \[[@CR24]\]Military Medical Science Press2010.01Clinical Research of Mesenchymal Stem CellsWang Tong \[[@CR25]\]People's Medical Publishing House Co., Ltd2011.08The Basis, Ethics and Principles of Clinical Applications of Stem CellsJin Kunlin \[[@CR26]\]Science Press2011.12Research Legal Regulation of Human Embryonic Stem CellZhao Xu \[[@CR27]\]Shanghai People's Publishing House2012.04Mesenchymal Stem Cells: Basic Research and Clinical ApplicationHan Zhongchao \[[@CR28]\]Science Press2012.10Clinical Research and Application of Stem CellsGu Yongquan, Han Zhongcao, Fu Xiaobing \[[@CR29]\]People's Medical Publishing House2012.10Application of Stem Cell Technology for Cardiovascular DiseasesMa Yitong, Ge Junbo \[[@CR30]\]People's Medical Publishing House2012.06Development Report on Technology and Industry of Stem CellDai Tao, Chi Hui, Fu Xiaobing, Pei Xuetao, Zhou Qi, Li Defu, Lan Baoshi \[[@CR31]\]Science Press2014.06Practice of Hematopoietic Stem Cell TransplantationHuang Xiaojun \[[@CR32]\]People's Medical Publishing House2014.07Clinical Progress of Stem Cell TherapyHan Zhongchao \[[@CR33]\]Tianjin Science and Technology Translation Publishing Co., LtdTable 4Main monographs of tissue engineering published in ChinaTimeNameAuthorPublishing Company2002.09Tissue EngineeringYang Zhiming \[[@CR34]\]Chemical Industry Press2003.08Repair of Medicine and Tissue EngineeringLao Weide \[[@CR35]\]Chemical Industry Press2004.06Principles and Protocol of Tissue EngineeringJin Yan \[[@CR36]\]Fourth Military Medical University Press2004.12The Theory and Practice of Tissue EngineeringCao Yilin \[[@CR37]\]Shanghai Scientific and Technical Publishers2005.06Basic and Clinic Research on Tissue EngineeringYang Zhiming \[[@CR38]\]Sichuan Scientific and Technological Press2006.05Tissue Engineering: A Laboratory ManualPei Guoxian, Wei Kuanhai, Jin Dan \[[@CR39]\]Military Medical Science Press2008.01Tissue EngineeringCao Yilin \[[@CR40]\]Science Press2009.05Tissue Engineering of SkinWu Jinjin, ZhuYoutang \[[@CR41]\]Military Medical Science Press2010.02Biomaterials and Tissue EngineeringXiong Dangsheng \[[@CR42]\]Science Press2011.03Stem Cell Tissue Engineering: Basic Theory and Clinical ApplicationWang Dianliang \[[@CR43]\]Science Press2012.01Introduction to Human Tissue EngineeringGuan Guangju, Jiang Duyin \[[@CR44]\]Shandong University Press2015.01Fabrication and Structure Performance of Biodegradable Tissue Engineering ScaffoldsCui Zhixiang \[[@CR45]\]National Defence Industry Press2015.06Medical Polysaccharide MaterialDan Huaping \[[@CR46]\]Science Press

International collaboration and opportunities for RM in China {#Sec9}
-------------------------------------------------------------

Open and cooperative regulations are basic in China. Since 2005, China has cooperated with many countries that are advanced in RM at different levels. Six world-renowned comprehensive RM research institutions from Germany, the USA, Canada, Spain, and The Netherlands established a Regenerative Medicine Coalition (RMC) to jointly promote the research and innovation of RM therapy at cellular levels (Table [5](#Tab5){ref-type="table"}). Even some large foreign pharmaceutical companies, such as General Electric and Sanofi-Aventis, have invested in China for stem cell-related research and achieved relevant results (<http://lib.cet.com.cn/paper/szb_con.aspx?id=140472>) \[[@CR47], [@CR48]\]. Also, the use of theories and skills of RM in military medicine is one of the important fields in the future \[[@CR49]\].Table 5Collaborations between China and other countries in regenerative medicine researchCountry of collaborationTimeObjectsFrance2005Institute of Zoology (IOZ), Chinese Academy of Sciences, and the French National Institute for Agricultural Research2007The Chinese-French Joint Laboratory of Biology of Embryonic Cells of MammalsAustralia2007Sino-Australia Center of Excellence for Stem Cell ScienceCanada2007Monash Immunology and Stem Cell Laboratories (MISCL) was awarded a federal government grant to establish a joint Australia-China Centre for Excellence in Stem Cell Science with Peking University.2009The Ministry of Science and Technology and the Canadian Institutes of Health Research signed a memorandum of understanding.UK2005The Committee of the National Natural Science Foundation of China and the UK Medical Research Council signed a memorandum of cooperation.2009Scottish Centre for Regenerative Medicine (SCRM) and Peking University Stem Cell Research Center (PKUSCRC) established a national international joint research center.2012UK Medical Research Council and the National Natural Science Fund Committee cooperated to jointly fund a stem cell research project.USA2009The California Institute for Regenerative Medicine (CIRM) and the Chinese Ministry of Science and Technology (MST) signed an agreement to collaborate on stem cell research.Germany2009The National Natural Science Fund Committee and the German Science Foundation cooperated to jointly fund a stem cell research project.

Conclusions {#Sec10}
===========

Great demands in RM are not only in China but also in the world. Their theories and key skills or products are used not only in peacetime but also in military field \[[@CR49]\]. The Chinese government attaches great importance to this field, and vigorous investments from the government and companies may accelerate the progress in basic research and translational application. Innovation and international cooperation will be emphasized in future studies. Other sound administrative system, laws, technical specifications, and guidelines are very important in pushing their healthy and orderly development.
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